I believe the anogential cancer human trials will start 2H23 using INV043 being conducted by Peter Mac. There is also meant to be a human trial on BCC in the 2H23 according to previous Ann's. My assumption is that they are using INV043 as that was the latest version developed by Hudson's that has been released to the market. Human trials were meant to begin in 2H20, Covid put a quick stop to that sadly. We can all have a guess what the SP may have been in 2023 if these trials had gone ahead and were as successful as the results on the 3 mice that Hudson's carried out on TNB cancer. The immune response it created, not being able to re-introduce the cancer into those mice is a game changer IMO
IVX Price at posting:
0.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)